ImmunoPrecise adds Jon Lieber to board of directors

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) appointed Jon Lieber to its board of directors, effective immediately, according to a company statement.

Lieber brings over 30 years of financial and strategic leadership experience in biotechnology and life sciences sectors. He currently serves as chief financial officer at Rallybio, a clinical-stage biotechnology company developing therapies for severe and rare diseases.

Previously, Lieber held the CFO position at Applied Genetic Technologies Corporation, a publicly traded gene therapy company, where he led capital-raising efforts and oversaw finance, human resources, investor relations, and IT operations. His career includes senior roles at Danforth Advisors, Histogenics, Repligen, Xcellerex, and Altus Pharmaceuticals, as well as investment banking positions at Salomon Brothers and SG Cowen.

Lieber currently serves on the board of directors of Salarius Pharmaceuticals, where he is a member of both the Audit Committee and the Nominating and Governance Committee.

"Jon brings the rare and highly valuable combination of Nasdaq board governance and senior executive experience—critical as we navigate commercialization and strategic growth," said Dr. Jennifer Bath, CEO of ImmunoPrecise.

ImmunoPrecise describes itself as an AI-powered biotherapeutics company that partners with pharmaceutical companies for drug discovery and development using its HYFT technology and LENSai platform.

You May Also Be Interested In

• Nasdaq rejects Triller shareholder authorization for discounted stock sales
• Palo Alto Networks (PANW) PT Raised to $330 at FBN Securities
• Xbox testing disc-to-digital feature that digitizes a physical game collection